NWBO
Northwest Biotherapeutics, Inc.
Set alert
0.17 USD 0.00 0.00%
0.166 Day range 0.1774
0.14 52-week range 0.34
- YTD
- -26.09%
- 1 year
- -29.17%
- Open
- 0.17
- Prev close
- 0.17
- Mkt cap
- 289.96M
- Vol
- 1.11M
- Avg vol
- 4.07M
- EPS
- -0.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.166
- High
- 0.1774
- Forward P/E
- 0.00
- Beta
- 0.55
- Short ratio
- 13.54
- Inst. own
- 42.60%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.407273
- 200-d avg
- 0.457338
- 1y target
- 5.00
Key statistics
- Market cap
- 62.75M
- Enterprise value
- 69.76M
- Trailing P/E
- -0.52
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 44.34
- Price / book
- 0.00
- EPS (TTM)
- -0.784
- Beta
- 0.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.42M
- Revenue growth
- -45.40%
- Free cash flow
- -84.42M
- Total cash
- 802.00K
- Total debt
- 21.09M
- Return on equity
- 0.00%
- Shares outstanding
- 153.41M
- Short % of float
- 15.09%
- 50-day average
- 0.407273
- 200-day average
- 0.457338
Analyst view
Consensus: buy
Buy
Price target (mean) 5.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NWBO Revenue — quarterly 200.00K
NWBO Net income — quarterly -26.83M
NWBO EPS — quarterly -0.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -0.02 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -0.02 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 5, 2024 | Dec 1, 2023 | 0.00 | -0.02 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.02 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | -0.01 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2014 | Oppenheimer | down | Outperform | Perform |
| Oct 15, 2013 | Oppenheimer | init | — | Outperform |
| Sep 18, 2013 | Summer Street Research | init | — | Buy |
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patients own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate, which is under Phase III for prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nwbio.com
News
- Northwest Biotherapeutics Announces Expansion of Its Technical Team
- Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
- Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production
- Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
- Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
- Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
- Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
- Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
- Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
Your note
Sign in to keep a note on NWBO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COGNATE BIOSERVICES, INC. | Beneficial Owner (10% or more) | Sale | Jun 29, 2015 | 18,460,390 |
| WOODFORD INVESTMENT MANAGEMENT LLP | Beneficial Owner (10% or more) | Ownership Statement | Nov 4, 2015 | 18,316,679 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Woodford Investment Management LLP | 20.79% | 25,915,937 | 13.99M | Sep 29, 2016 |
| Credit Suisse/ | 1.52% | 1,898,904 | 1.03M | Sep 29, 2016 |
| Vanguard Group, Inc. (The) | 1.11% | 1,378,939 | 744.63K | Sep 29, 2016 |
| Goldman Sachs Group, Inc. | 0.80% | 994,696 | 537.13K | Sep 29, 2016 |
| BlackRock Institutional Trust Company, N.A. | 0.58% | 717,911 | 387.67K | Sep 29, 2016 |
| Millennium Management LLC | 0.29% | 357,411 | 193.00K | Sep 29, 2016 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.78% | 968,768 | 561.88K | Jun 29, 2016 |
| Vanguard Extended Market Index Fund | 0.44% | 546,665 | 317.06K | Jun 29, 2016 |
| Fidelity Extended Market Index Fund | 0.13% | 158,536 | 53.90K | Aug 30, 2016 |
| Fidelity Total Market Index Fund | 0.05% | 60,544 | 20.58K | Aug 30, 2016 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.03% | 33,900 | 19.66K | Jun 29, 2016 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 27,004 | 9.18K | Aug 30, 2016 |